Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023)

Table 1 The top ten co-cited documents

	Title	Year	Type	First author	Journal	IF (2021)	JCR	Co-citation	DOI	Impact index per article
1	Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer	2012	Clinical trial	Brahmer JR	N Engl J Med	176.08	Q1	5555	10.1056/NEJMoa1200694	524.5
2	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study	2016	Clinical trial	Nanda R	J Clin Oncol	50.72	Q1	1297	10.1200/JCO.2015.64.8931	133.7
3	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis	2010	Review	Paoletti X	JAMA	157.34	Q1	604	10.1001/jama.2010.534	47.9
4	Progress in the treatment of advanced gastric cancer	2017	Review	Song ZY	Tumour Biol	3.65 (2016)	Q2	490	10.1177/1010428317714626	75.7
5	m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer	2020	Article	Zhang B	Mol Cancer	41.44	Q1	442	10.1186/s12943-020-01170-0	134.0
6	PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer	2019	Article	Kamada T	Proc Natl Acad Sci U S A	12.78	Q1	428	10.1073/pnas.1822001116	106.8
7	Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures	2019	Article	Zeng DQ	Cancer Immunol Res	12.02	Q1	418	10.1158/2326-6066.CIR-18-0436	93.7
8	PD-L1 expression in human cancers and its association with clinical outcomes	2016	Review	Wang X	Onco Targets Ther	4.35	Q2	412	10.2147/OTT.S105862	59.0
9	Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer	2019	Article	Kather JN	Nat Med	87.24	Q1	400	10.1038/s41591-019-0462-y	114.0
10	The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial	2010	Clinical trial	Heiss MM	Int J Cancer	7.32	Q1	349	10.1002/ijc.25423	30.8

JCR: Journal Citation Reports; IF: Impact Factor.

Table 2 Clinical trials in phase 3 and phase 4 (or phase 2/3)

No.	Trial ID	Status	Phases	Start date	Title
1	NCT00503321	Terminated	Phase 2/3	October 1, 2006	Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma
2	EUCTR2017-004896-30-IE	Not recruiting	Phase 3	July 6, 2018	A Randomized, Active-Controlled, Blinded, Phase III Clinical Trial of BMS- 986213 (Fixed Dose Combination of Relatlimab [anti-LAG-3] and Nivolumab) in Combination with Chemotherapy versus Placebo in Combination with Chemotherapy as First-Line Treatment in Participants with Unresectable, Locally Advanced or Metastatic LAG-3 Positive Gastric or Gastroesophageal Junction Adenocarcinoma
3	NCT04078152	Active, not recruiting	Phase 4	September 5, 2019	Durvalumab Long-Term Safety and Efficacy Study
4	ChiCTR2000039110	Recruiting	Phase 4	October 14, 2020	Effect of immunotherapy combined with chemotherapy on gastric cancer
5	NCT05002686	Recruiting	Phase 2/3	August 7, 2021	Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
6	NCT05152147	Recruiting	Phase 3	December 2, 2021	A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
7	NCT05270824	Not yet recruiting	Phase 3	March 1, 2022	Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma
8	NCT05325528	Recruiting	Phase 2/3	April 4, 2022	Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases
9	NCT05677490	Not yet recruiting	Phase 3	January 6, 2023	mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
10	NCT05699655	Not yet recruiting	Phase 2/3	March 1, 2023	Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV, Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer